Status:
UNKNOWN
Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza)
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Pneumonia, Viral
Eligibility:
FEMALE
18+ years
Brief Summary
Severe Acute Respiratory Infection (SARI) is defined by the World Health Organization (WHO) as acute respiratory infection with a history of fever ≥38°C and cough for less than 10 days duration that r...
Eligibility Criteria
Inclusion
- Admission to an acute care or intensive care unit with a clinical syndrome of lower respiratory tract infection suspicious for viral SARI:
- fever
- cough
- AND (radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) OR SpO2 ≤ 94% on room air OR requiring new supplemental oxygen (above baseline if preexisting) OR requiring invasive or non-invasive mechanical ventilation).
- confirmed viral cause for SARI by respiratory viral RT-PCR testing.
Exclusion
- Prisoners or wards of the state
- Inability to consent or lack of availability of legal surrogate
- Do not attempt resuscitation/do not intubate status on admission
Key Trial Info
Start Date :
April 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04786301
Start Date
April 30 2020
End Date
March 1 2022
Last Update
March 12 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bellevue Hospital Center
New York, New York, United States, 10016
2
NYU Langone Medical Center
New York, New York, United States, 10016